A potential coronavirus vaccine developed by China appears safe and provokes immune responses in a combination of early and intermediate-stage tests in humans, according to a new study.
The Covid-19 vaccine candidate, known as BBIBP-Corv, is being developed by the Beijing Institute of Biological Products in collaboration with the state-run China National Pharmaceutical Group. A report published in The lancet on Thursday described the vaccine overall as “safe” and “well tolerated”.
The BBIBP-Corv studies in human participants began in early June after the vaccine showed strong results in monkeys and raised antibodies without causing complications, the researchers said.
In the first two phases of his study, the vaccine did not cause any serious side effects. After the The lancetThe most common mild to moderate side effects included fever and pain at the injection sites.
The results are from Phase I and Phase II of the vaccine study, which was conducted between April 29 and July 30 with 600 healthy participants aged 18 to 80 years.
However, antibody levels in participants over 60 were lower and sometimes took up to 42 days to increase significantly. It took younger participants an average of 28 days to generate an antibody response.
Professor Xiaoming Yang, one of the study’s authors, said, “Protecting the elderly is a key goal of a successful Covid-19 vaccine as this age group is at higher risk for serious illness.
“However, vaccines are sometimes less effective in this group because the immune system becomes weaker with age. It is therefore encouraging to see that BBIBP-CorV elicits antibody responses in people 60 and older, and we believe this warrants further investigation. ”
BBIBP-CorV is one of at least 10 coronavirus vaccine projects worldwide that have entered Phase III trials, four of which are led by Chinese scientists, according to the World Health Organization.
China has focused on developing five types of vaccines and at least one clinical study is being conducted for each method. A total of 11 vaccine candidates are in various stages of testing, Yang Sheng, deputy director of the National Medical Products Administration’s drug registration bureau, told the state China Daily in September.
These were the details of the news The Chinese coronavirus vaccine shows promising results when tested in humans,... for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at de24.news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
